Literature DB >> 6331298

Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

T Sakuma.   

Abstract

Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) were isolated from varicella-zoster virus-infected Vero cells which were pulse-treated with 5-iododeoxyuridine or 5-bromodeoxyuridine or both and then treated with BV-araU. These BV-araU-resistant strains (BV-araUr) could not be isolated from varicella-zoster virus-infected cells treated with BV-araU alone and had reduced viral thymidine kinase activity. Two of five BV-araUr strains were also resistant to 5-iododeoxyuridine and 5-bromodeoxyuridine, whereas other BV-araUr strains were relatively susceptible to these drugs. All clones from the BV-araUr strain were susceptible to 1-beta-D-arabinofuranosylcytosine and phosphonoacetic acid, but 7 of 10 clones from the BV-araUr strain were resistant to 1-beta-D-arabinofuranosyladenine. The possible mechanisms of induction of BV-araU resistance are discussed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6331298      PMCID： PMC185633          DOI： 10.1128/AAC.25.6.742

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Possible peptide chain termination mutants in thymide kinase gene of a mammalian virus, herpes simplex virus.

Authors:  W P Summers; M Wagner; W C Summers
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  A novel approach to study the DNA of herpes zoster virus.

Authors:  F Rapp; J P Iltis; J E Oakes; R W Hyman
Journal:  Intervirology       Date:  1977       Impact factor: 1.763

3.  Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells.

Authors:  T Hackstadt; L P Mallavia
Journal:  J Virol       Date:  1978-02       Impact factor: 5.103

4.  Induction of both thymidine and deoxycytidine kinase activity by herpes viruses.

Authors:  A T Jamieson; G A Gentry; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1974-09       Impact factor: 3.891

5.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

6.  Resistance of herpes simplex virus to acycloguanosine--genetic and physical analysis.

Authors:  C S Crumpacker; P Chartrand; J H Subak-Sharpe; N M Wilkie
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

7.  Location of non-temperature-sensitive genes on the genetic map of herpes simplex virus type 1.

Authors:  S M Brown; A T Jamieson
Journal:  IARC Sci Publ       Date:  1978

8.  Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus.

Authors:  H J Field; G Darby; P Wildy
Journal:  J Gen Virol       Date:  1980-07       Impact factor: 3.891

9.  Induction of deoxypyrimidine kinase activity in human embryonic lung cells infected with varicella-zoster virus.

Authors:  T Ogino; T Otsuka; M Takahashi
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

10.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

Authors:  D M Coen; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205
View more
  10 in total

1.  In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains.

Authors:  M Baba; K Konno; S Shigeta; E De Clercq
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

2.  Rapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.

Authors:  T Suzutani; M Saijo; M Nagamine; M Ogasawara; M Azuma
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

3.  Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2.

Authors:  T Suzutani; H Machida; T Sakuma; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

4.  Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.

Authors:  T Suzutani; H Machida; T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

5.  Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.

Authors:  G Abele; B Eriksson; J Harmenberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Identification of varicella-zoster virus strains by PCR analysis of three repeat elements and a PstI-site-less region.

Authors:  M Takada; T Suzutani; I Yoshida; M Matoba; M Azuma
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.

Authors:  S Koyano; T Suzutani; I Yoshida; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Antiviral activity of oxetanocins against varicella-zoster virus.

Authors:  T Sakuma; M Saijo; T Suzutani; I Yoshida; S Saito; M Kitagawa; S Hasegawa; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Random mutagenesis of the thymidine kinase gene of varicella-zoster virus.

Authors:  T Suzutani; S F Lacey; K L Powell; D J Purifoy; R W Honess
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 10.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.